Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

This article was originally published here

ARDS is an area of significant unmet need, with an approximate 40% mortality rate with current standard of care, which includes prolonged ICU treatment and mechanical ventilation.1,2 As

The post Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply